Related Experiment Video
Updated: Aug 10, 2026
06:55
Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis
Published on: February 13, 2026
Digital Pathology-Enabled Artificial Intelligence for Fibrosis Assessment in Metabolic Dysfunction-Associated
1Department of Pathology, Institute of Liver & Biliary Sciences, D-1 Vasant Kunj, New Delhi, 110070, India.
Journal of Clinical and Experimental Hepatology
|August 9, 2026
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) diagnosis faces challenges due to inconsistent histology scoring. Digital pathology and AI offer a promising solution for objective and reproducible MASH assessment in drug trials.
Area of Science:
- Hepatology and Digital Pathology
- Artificial Intelligence in Medical Diagnostics
- Drug Development for Liver Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern.
- Current diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) relies on subjective histological scoring, leading to reproducibility issues in clinical trials.
- Most MASH drug candidates have failed, highlighting the need for improved trial methodologies.
Purpose of the Study:
- To address the limitations of subjective histological scoring in MASH diagnosis and clinical trials.
- To explore the potential of digital pathology (DP) integrated with artificial intelligence (AI) for objective MASH assessment.
- To evaluate the performance of deep learning (DL) models in analyzing liver fibrosis and other MASH features.
Main Methods:
- Development and validation of deep learning (DL) models using digitized tissue slides from MASH studies.
- Application of AI algorithms for quantitative analysis of histological features, particularly liver fibrosis.
- Comparison of AI-driven assessments with traditional histopathological scoring.
Main Results:
- AI models demonstrate superior reproducibility and granularity in quantifying MASH features, especially liver fibrosis progression and regression.
- AI tools improve pathologist concordance, standardize scoring, and assist in predicting clinical outcomes.
- AI-based approaches show potential for more reliable endpoint decisions in MASH drug trials.
Conclusions:
- Digital pathology coupled with AI offers a powerful solution to enhance the objectivity and reproducibility of MASH histological assessment.
- AI-driven tools can significantly improve the efficiency and reliability of MASH drug development.
- Overcoming implementation challenges is crucial for widespread adoption of DP-enabled AI in MASLD clinical practice and trials.
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...